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Abstract
Background: Both Taxotere and Capecitabine have shown anti-cancer activity against various
cancers including prostate cancer. In combination, Taxotere plus Capecitabine has demonstrated
higher anti-cancer activity in advanced breast cancers. However, the molecular mechanisms of
action of Taxotere and Capecitabine have not been fully elucidated in prostate cancer.
Methods: The total RNA from PC3 and LNCaP prostate cells untreated and treated with 2 nM
Taxotere, 110 µM Furtulon (active metabolite of Capecitabine), or 1 nM Taxotere plus 50 µM
Furtulon for 6, 36, and 72 hours, was subjected to Affymetrix Human Genome U133A Array
analysis. Real-time PCR and Western Blot analysis were conducted to confirm microarray data.
Results: Taxotere and Furtulon down-regulated some genes critical for cell proliferation, cell cycle
progression, transcription factor, cell signaling, and oncogenesis, and up-regulated some genes
related to the induction of apoptosis, cell cycle arrest, and differentiation in both cell lines.
Taxotere and Furtulon also up-regulated some genes responsible for chemotherapeutic resistance,
suggesting the induction of cancer cell resistance to these agents.
Conclusions: Taxotere and Furtulon caused the alternation of a large number of genes, many of
which may contribute to the molecular mechanisms by which Taxotere and Furtulon inhibit the
growth of prostate cancer cells. This information could be utilized for further mechanistic research
and for devising optimized therapeutic strategies against prostate cancer.
Background
Prostate cancer is the most common cancer and the sec-
ond leading cause of cancer related deaths in men in the
United States with an estimated 230,110 new cases and
29,500 deaths in 2004 [1]. Initial treatment for prostate
cancer is usually androgen-ablative therapy, radiotherapy
or radical prostatectomy and the patients respond to
androgen-ablative therapy in the beginning of treatment.
However, many patients eventually fail this therapy and
die of recurrent androgen-independent prostate cancer
and metastasis [2]. Up to 30% of men undergoing radical
prostatectomy will also relapse, often as a result of
micrometastatic cancer present at the time of surgery [3].
The efficacy of cytotoxic chemotherapy for treatment of
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hormone-refractory prostate cancer has been tested in
clinical trials. In general, response rates of <10% were
observed in single-agent studies [2]. Thus, there is a tre-
mendous need for the development of mechanism-based
targeted strategies for treatment of prostate cancer.
Taxotere, a member of taxane family, is semi-synthesized
from an inactive taxoid precursor extracted from the nee-
dles of the European yew, Taxus baccata. Its known basic
mechanism of action is that it binds to tubulin and
deranges the equilibrium between microtubule assembly
and disassembly during mitosis [4]. Stabilization of
microtubules by Taxotere impairs mitosis and exerts an
anticancer effect in tumors [4]. Taxotere has shown clini-
cal activity in wide spectrum of solid tumors including
breast, lung, ovarian, prostate cancers, etc [5,6]. In meta-
static breast, lung, and ovarian cancer, randomized trials
have shown that Taxotere-containing therapies are supe-
rior to or as effective as established standard chemothera-
peutic regimens and are often associated with an
improved safety profile [6]. Clinical trials have also found
that weekly Taxotere in patients with metastatic hormone-
refractory prostate cancer is associated with improve-
ments in clinical benefit response and quality of life [7,8].
Thus, Taxotere is currently considered to be among the
most important anticancer drugs in cancer chemotherapy.
In addition to its effects on microtubules, Taxotere also
induces apoptosis with down-regulation of bclXL and bcl-
2, and upregulation of p21WAF1 and p53 [9,10]. We have
previously reported that Taxotere down-regulates some
genes for cell proliferation, mitotic spindle formation,
transcription factors, and oncogenesis, and up-regulates
some genes related to induction of apoptosis and cell
cycle arrest in prostate cancer cells, suggesting the pleio-
tropic effects of Taxotere on prostate cancer cells [11].
Capecitabine is an orally administered systemic prodrug
of 5'-deoxy-5-fluorouridine (5-DFUR or Furtulon) which
is converted to 5-fluorourasil (5-FU) [12]. Capecitabine is
readily absorbed from the gastrointestinal tract. In human
and animals, carboxylesterase hydrolyzes much of
Capecitabine to 5'-deoxy-5-flurocytidine (5-DFCR). Cyti-
dine deaminase, an enzyme found in most tissues includ-
ing tumors, subsequently converts 5-DFCR to 5-DFUR.
The enzyme, thymidine phosphorylase (dThdPase), then
hydrolyzes 5-DFUR to the active drug 5-FU both in vivo
and in vitro. After being converted to 5-FU, Capecitabine
inhibits essential cellular biosynthetic processes and is
incorporated into DNA to inhibit normal bioprocess
function of the cell [13]. Capecitabine has shown anti-
tumor activity in various cancers including prostate cancer
[14-16]. 5-FU-based chemotherapy improves overall and
disease-free survival of patients with cancer. However,
response rates for 5-FU-based chemotherapy are low and
a large number of tumors eventually becomes resistant to
5-FU [13,17].
Clinical trials showed that chemotherapeutic combina-
tion with Taxotere and Capecitabine resulted in improved
objective response rate and overall survival without a sig-
nificant increase in the treatment related adverse effects in
metastatic breast cancer and advanced non-small cell lung
carcinoma [18,19]. However, the molecular mecha-
nism(s) of action of Taxotere and Capecitabine have not
been fully elucidated. In this study, we utilized high-
throughput gene chip, which contains 22,215 known
genes, to determine the alternation of gene expression
profiles of hormone insensitive (PC3) and sensitive
(LNCaP) prostate cancer cells exposed to Taxotere and
Furtulon. The purpose of this study was: 1) to identify
novel genes that have key roles in cancer cell killing and
resistance induced by Taxotere and/or Furtulon; 2) to test
whether similar genes are altered by Taxotere and Furtu-
lon; 3) to test whether combination therapy alters genes
that may reflect better treatment outcome or may provide
information whether combination therapy could be
antagonistic; 4) finally to provide molecular information
for further mechanistic investigation and future clinical
application.
Methods
Cell culture and growth inhibition
PC3 (ATCC, Manassas, VA) and LNCaP (ATCC) human
prostate cancer cells were cultured in RPMI-1640 media
(Invitrogen, Carlsbad, CA) supplemented with 10% fetal
bovine serum and 1% penicillin and streptomycin in a 5%
CO2atmosphere at 37°C. Taxotere (Aventis Pharmaceuti-
cals, Bridgewater, NJ) was dissolved in DMSO to make 4
µM stock solution. Furtulon (Roche, Palo Alto, CA) was
dissolved in PBS to make 100 mM stock solution. For
growth inhibition, PC3 and LNCaP cells were treated with
Taxotere (1, 2, and 4 nM), Furtulon (50, 100, and 200
µM), or 1 nM Taxotere plus 50 µM Furtulon for one to
three days. Control PC3 and LNCaP cells received 0.01%
DMSO or 0.1% PBS for same time points. After treatment,
PC3 and LNCaP cells were incubated with MTT (0.5 mg/
ml, Sigma, St. Louis, MO) at 37°C for two hours and then
with isopropyl alcohol at room temperature for one hour.
The spectrophotometric absorbance of the samples was
determined by using ULTRA Multifunctional Microplate
Reader (TECAN, Durham, NC) at 595 nm. The concentra-
tions of Taxotere and Furtulon used for our in vitro studies
are easily achievable in humans, suggesting that our
experimental results are relevant for human applications.
The experiment was repeated three times and a t test was
performed to verify the significance of cell growth inhibi-
tion after treatment.BMC Cancer 2005, 5:7 http://www.biomedcentral.com/1471-2407/5/7
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Microarray analysis for gene expression profiles
PC3 and LNCaP cells were treated with 2 nM Taxotere,
110 µM Furtulon, or 1 nM Taxotere plus 50 µM Furtulon
for 6, 36, and 72 h. Total RNA from each sample was iso-
lated by Trizol (Invitrogen, Carlsbad, CA) and purified by
RNeasy Mini Kit and RNase-free DNase Set (QIAGEN,
Valencia, CA) according to the manufacturer's protocols.
cDNA for each sample was synthesized by Superscript
cDNA Synthesis Kit (Invitrogen, Carlsbad, CA) using the
T7-(dT)24 primer instead of the oligo(dT) provided in the
kit. Then, the biotin-labeled cRNA was transcripted in vitro
from cDNA by using BioArray HighYield RNA Transcript
Labeling Kit (ENZO Biochem, New York, NY), and puri-
fied by RNeasy Mini Kit. The purified cRNA was frag-
mented by incubation in fragmentation buffer (40 mM
Tris-acetate pH 8.1, 100 mM KOAc, 30 mM MgOAc) at
95°C for 35 min and chilled on ice. The fragmented
labeled cRNA was applied to Human Genome U133A
Array (Affymetrix, Santa Clara, CA), which contains
22,215 human gene probes, and hybridized to the probes
in the array. After washing and staining, the arrays were
scanned. Two independent experiments were performed
to verify the reproducibility of results.
Microarray data normalization and analysis
The gene expression levels of samples were normalized
and analyzed by using Microarray Suite, MicroDB™, and
Data Mining Tool software (Affymetrix, Santa Clara, CA).
The absolute call (present, marginal, absent) and average
difference of 22,215 gene expressions in a sample, and the
absolute call difference, fold change, average difference of
gene expressions between two or several samples were
normalized and identified using these software. Statistical
analysis of the mean expression average difference of
genes, which show >2 fold change, was performed using a
t test between treated and untreated samples. Clustering
and annotation of the gene expression were analyzed by
using Cluster and TreeView [20], Onto-Express [21], and
GenMAPP [22]. Genes that were not annotated or not eas-
ily classified were excluded from the functional clustering
analysis.
Real-time RT-PCR analysis for gene expression
To verify the alterations of gene expression at the mRNA
level, which appeared on the microarray, we chose repre-
sentative genes (Table 1) with varying expression profiles
for real-time RT-PCR analysis. Two micrograms of total
RNA from each sample were subjected to reverse tran-
scription using the Superscript first strand cDNA synthesis
kit (Invitrogen, Carlsbad, CA) according to the manufac-
turer's protocol. Real-time PCR reactions were then car-
ried out in a total of 25 µL reaction mixture (2 µl of cDNA,
12.5 µl of 2X SYBR Green PCR Master Mix, 1.5 µl of each
5 µM forward and reverse primers, and 7.5 µl of H2O) in
SmartCycler II (Cepheid, Sunnyvale, CA). The PCR pro-
gram was initiated by 10 min at 95°C before 40 thermal
cycles, each of 15 s at 95°C and 1 min at 60°C. Data were
analyzed according to the comparative Ct method and
were normalized by actin expression in each sample.
Melting curves for each PCR reaction were generated to
ensure the purity of the amplification product.
Western blot analysis
We also conducted Western Blot analysis to verify the
alterations of genes at the level of translation for selected
genes with varying expression profiles. The PC3 and
LNCaP cells were treated with 1 and 2 nM Taxotere or 50
and 110 µM Furtulon for 24, 48, and 72 hours. After treat-
ment, the cells were lysed in 62.5 mM Tris-HCl and 2%
SDS, and protein concentration was measured using BCA
protein assay (PIERCE, Rockford, IL). The proteins were
subjected to 10% or 14% SDS-PAGE, and electrophoreti-
cally transferred to nitrocellulose membrane. The mem-
branes were incubated with anti-cathepsin C (1:200,
Santa Cruz, Santa Cruz, CA), anti-p16 (1:200, Santa Cruz,
Table 1: The primers used for real-time RT-PCR analysis
Genes Primer Sequence PCR Product
ATF5 ctc ctc ctt ctc cac ctc aa
gcc gac ttg ttc tgg tct ct
103 bp
Cyclin A2 aat cag ttt ctt acc caa tac
ctg atg gca aat act tga
127 bp
Fas/Apo-1 caa aag tgt taa tgc cca agt
gca gtc tgg ttc atc cc
187 bp
FOXM1 gcc aca ctt agc gag acc c
atc aca agc att tcc gag aca
189 bp
GADD45 cgc ctg tga gtg agt gc
ctt atc cat cct ttc ggt ctt
154 bp
IGFBP2 atg ggc gag ggc act t
cag ctc ctt cat acc cga ctt
189 bp
uPA ggg agc aga gac act aac gac t
ctc aca gcc cac aca aca ag
108 bp
Ki-67 ccg ggc tcc atc atc t
ctc cag acg cca aaa taa gac
148 bp
p21WAF1 ctg gag act ctc agg gtc gaa
gga tta ggg ctt cct ctt gga
98 bp
p27KIP1 cgc tcg cca gtc cat t
aca aaa ccg aac aaa aca aag
187 bp
PIR cac tag ccc tcc atc ctc tac
ggg tct gcc aat gct tct
151 bp
MMP1 gct ttc ctc cac tgc tgc t
aac ttg cct ccc atc att ctt
146 bp
STK6 tca gcg ggt ctt gtg t
ctc ttt tgg gtg tta ttc agt
162 bp
Survivin cca ctg ccc cac tga gaa c
acc gga cga atg ctt ttt atg
118 bp
TRIP13 tct ggc agt gga caa gca gtt
tgg gag acg gct gtg tgg
136 bp
GAPDH ctg cac cac caa ctg ctt ag
ttc agc tca ggg atg acc tt
222 bp
β-actin cca cac tgt gcc cat cta cg
agg atc ttc atg agg tag tca gtc ag
99 bpBMC Cancer 2005, 5:7 http://www.biomedcentral.com/1471-2407/5/7
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Santa Cruz, CA), anti-IKKα (1:100, Santa Cruz, Santa
Cruz, CA), anti-p21WAF1 (1:500, Upstate, Lake Placid, NY),
anti-Bax (1:10000, Trevigen, Gaithersburg, MD), anti-sur-
vivin (1:200, Alpha Diagnostic, San Antonio, TX), anti-
CDC2 (1:200, Santa Cruz, Santa Cruz, CA), anti-cyclin A
(1:250, NeoMarkers, Union City, CA), anti-cyclin B
(1:200, Santa Cruz, Santa Cruz, CA), anti-cyclin E (1:250,
NeoMarkers), and anti-β-actin (1:10000, Sigma, MO) pri-
mary antibodies, and subsequently incubated with sec-
ondary antibody conjugated with fluorescence dye. The
signal was then detected and quantified by using Odyssey
infrared imaging system (LI-COR, Lincoln, NE).
Effects of Taxotere and/or Furtulon on the growth of PC3 and LNCaP Cells Figure 1
Effects of Taxotere and/or Furtulon on the growth of PC3 and LNCaP Cells. PC3 and LNCaP prostate cancer cells treated 
with Taxotere and/or Furtulon resulted in a dose and time-dependent inhibition of cell proliferation (* : p < 0.05, n = 3)BMC Cancer 2005, 5:7 http://www.biomedcentral.com/1471-2407/5/7
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Table 2: Fold change of genes in PC3 cells exposed to combination treatment or mono-treatment with Taxotere or Furtulon
Gene Taxotere Furtulon Taxotere+Furtulon
6 h 36 h 72 h 6 h 36 h 72 h 6 h 36 h 72 h
Cell cycle and apoptosis
NM_001237.1 cyclin A2 (CCNA2) NC -1.1 -2.0 -1.1 -1.7 -3.0 -1.1 -1.4 -2.5
BE407516 cyclin B1 -1.1 -1.1 -2.3 NC -3.0 -6.1 -1.1 -3.0 -5.3
NM_001761.1 cyclin F (CCNF) -1.3 -1.3 -2.5 -1.5 -2.5 -2.6 -1.6 -1.6 -2.5
NM_014303.1 pescadillo homolog 1 NC -1.5 -2.3 1.3 -1.9 -2.6 -1.1 -2.1 -3.5
NM_003132.1 spermidine synthase (SRM) NC -1.5 -2.5 -1.1 -1.3 -2.5 -1.1 -1.1 -2.3
NM_000389.1 cyclin-dependent kinase inhibitor 1A (p21, Cip1) 1.7 1.0 2.6 1.9 2.6 3.5 NC 1.7 3.5
NM_003914.1 cyclin A1 (CCNA1) 1.3 2.3 2.8 NC 1.5 2.5 NC NC 2.0
L49506.1 cyclin G2 -2.1 2.0 2.6 -2.8 2.3 2.3 NC 3.7 2.5
NM_004354.1 cyclin G2 (CCNG2) -1.9 3.0 3.2 NC 2.5 2.3 1.0 4.6 3.5
AL535380 B-cell translocation gene 1, anti-proliferative 1.1 1.7 3.5 NC 1.4 2.8 -1.5 1.6 2.6
NM_006472.1 upregulated by 1,25-dihydroxyvitamin D-3 (VDUP1) 1.3 2.1 -2 1.0 2.1 2.3 1.0 2.3 NC
NM_015675.1 growth arrest and DNA-damage-inducible, beta (GADD45B) 1.2 2.5 6.5 1.6 1.5 2.6 1.0 NC 3.5
AF087853.1 growth arrest and DNA damage inducible protein beta NC 2.0 4.6 1.3 1.2 2.3 NC NC 3.2
AF078077.1 growth arrest and DNA-damage-inducible protein GADD45beta 1.5 2.0 5.3 1.1 1.2 2.1 NC 1.4 2.8
Transcription and translation
NM_007111.1 transcription factor Dp-1 (TFDP1) NC -1.6 -3.2 -1.3 -1.1 -2.0 NC -1.1 -2.0
NM_012068.2 activating transcription factor 5 (ATF5) NC -2.1 -3.5 NC -1.5 -2.1 -1.3 -1.1 -2.6
NM_012251.1 transcription factor A, mitochondrial (TFAM) 1.3 -1.5 -2.5 NC -1.6 -2.0 -1.1 -2.0 -3.7
AF220509.1 transcription associated factor TAFII31L NC -2.3 -3.2 -1.3 -1.3 -2.3 NC -1.2 -5.7
AA393940 eukaryotic translation initiation factor 5A -1.3 -1.5 -3.0 -1.6 -2.0 -3.5 -1.1 -1.1 -2.0
NM_001674.1 activating transcription factor 3 (ATF3) 1.4 1.9 14.9 1.5 2.1 3.5 1.1 2.6 4.9
Oncogenesis and other
NM_001511.1 GRO1 oncogene (GRO1) 2 -1.5 -3.0 1.7 1.2 -2.0 NC NC -4.0
NM_002090.1 GRO3 oncogene (GRO3) 2.8 -3.0 -4.0 2.5 -1.4 -6.5 NC -2.8 -13.9
NM_005754.1 Ras-GTPase-activating protein SH3-domain-binding protein NC -1.7 -2.8 NC -2.0 -2.5 NC -2.6 -4.6
NM_000026.1 adenylosuccinate lyase (ADSL) NC -1.3 -2.5 NC -1.4 -2.6 NC -1.6 -3.0
M80261.1 apurinic endonuclease (APE) -1.1 -1.4 -3.0 -1.1 -1.9 -2.6 NC -2.1 -3.7
D13413.1 tumor-associated 120 kDa nuclear protein p120 -1.1 -2.0 -3.2 -1.7 -1.7 -2.5 -2.3 -1.1 -3.0
AI743685 methionine aminopeptidase; eIF-2-associated p67 NC -2.6 -2.0 1.5 -1.5 -3.2 NC -2.3 -2.8
NM_002634.2 prohibitin (PHB) NC -1.4 -3.0 NC -1.9 -2.1 NC -1.5 -2.6
NM_002546.1 osteoprotegerin 1.5 -1.3 -3.0 1.2 -2.1 -3.0 NC -2.8 -5.3
AF003934.1 prostate differentiation factor mRNA -1.5 4.3 26.0 -1.7 4.9 16.0 NC 4.3 12.1
NM_000177.1 gelsolin (amyloidosis, Finnish type) (GSN) NC 1.5 2.8 NC 2.0 3.5 NC 1.9 2.3
Invasion and metastasis
NM_003254.1 tissue inhibitor of metalloproteinase 1 (TIMP1) NC 2.0 2.5 NC 2.6 3.7 NC 2.6 3.7
NM_003255.2 tissue inhibitor of metalloproteina(TIMP2) NC 1.6 2.5 NC 2.3 3.5 NC 1.6 3.5
NM_002638.1 protease inhibitor 3 (PI3) 1.2 2.0 2.0 1.1 3.7 5.7 1.0 3.0 4.6
NM_005562.1 laminin, gamma 2 (nicein (100 kD) 1.3 1.5 2.0 1.1 2.5 3.7 NC 2.3 3.7
NM_001908.1 cathepsin B (CTSB) NC 1.7 3.0 NC 1.7 2.8 1.1 1.3 2.5
NM_002658.1 plasminogen activator, urokinase (PLAU) NC 2.3 3.5 NC 2.8 2.3 1.0 2.1 1.9
NM_000930.1 plasminogen activator, tissue (PLAT) 1.1 2.5 4.6 NC 5.7 9.8 NC 3.2 4.9
NM_002421.2 matrix metalloproteinase 1 (MMP1) NC 1.4 4.3 NC 4.9 18.4 NC 5.7 13.0
NM_004994.1 matrix metalloproteinase 9 (MMP9) 1.1 1.7 2.0 1.0 1.9 2.0 NC 2.5 2.1
NM_000435.1 Notch homolog 3 (NOTCH3) NC 2.0 2.6 -2 2.3 3.2 NC 3.5 3.5
Resistance to chemotherapeutic agents
NM_000499.2 cytochrome P450, subfamily I (CYP1A1) 1.4 3.0 4.0 NC 3.5 5.3 1.2 9.2 10.6
NM_006697.1 cisplatin resistance associated (CRA) 1.0 1.7 2.0 -1.3 2.0 2.6 NC NC 2.6
NM_005980.1 S100 calcium-binding protein P (S100P) -1.2 4.9 24.3 1.1 10.6 27.9 NC 6.5 19.7
NM_002961.2 S100 calcium-binding protein A4 (S100A4) 3.0 3.7 5.3 1.0 5.7 11.3 2.8 6.5 10.6
NM_020672.1 S100-type calcium binding protein A14 (LOC57402) NC 1.5 2.0 NC 2.1 2.6 1.1 1.6 2.1
NM_001894.1 casein kinase 1, epsilon (CSNK1E) NC 1.7 3.2 NC 2.0 2.6 1.1 1.7 3.2
NM_000700.1 annexin A1 (ANXA1) NC 1.9 2.3 NC 2.0 2.3 NC 1.6 2.1
The genes in this list showed a >2 fold change in expression in at least one time point in both mono and combination treatment.
NC: No change; Negative value: Decrease; Positive value: Increase.BMC Cancer 2005, 5:7 http://www.biomedcentral.com/1471-2407/5/7
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Results
Cell growth inhibition
MTT assay showed that the treatment of PC3 and LNCaP
prostate cancer cells with Taxotere, Furtulon, or lower
concentration of Taxotere plus Furtulon resulted in dose
and time-dependent inhibition of cell proliferation (Fig-
ure 1), demonstrating the inhibitory effect of Taxotere and
Furtulon on the growth of PC3 and LNCaP prostate cancer
cells.
Regulation of mRNA expression by Taxotere and Furtulon 
treatment
Microarray analysis showed that the alterations of gene
expression were occurred as early as 6 hours of Taxotere
and/or Furtulon treatment, and were more evident with
longer treatment (Table 2 and 3).
Clustering analysis based on gene function showed down-
regulation of some genes for cell proliferation and cell
cycle progression (cyclin A, cyclin F, CDC2, CDK2, etc),
transcription factors (transcription factor A, ATF5,
TAF1131L, FOXM1, etc), and oncogenesis (GRO onco-
Table 3: Fold change of genes in LNCaP cells exposed to combination treatment or mono-treatment with Taxotere or Furtulon
Gene Taxotere Furtulon Taxotere+Furtulon
6 h 36 h 72 h 6 h 36 h 72 h 6 h 36 h 72 h
Cell cycle and apoptosis
NM_001786.1 cell division cycle 2 (CDC2) -1.2 -7.5 -12.1 -1.1 -2.8 -1.6 NC -4.0 -14.9
D88357.1 mRNA for CDC2 delta T -1.1 -6.1 -14.9 NC -2.8 -1.6 -1.1 -4.3 -13.0
NM_001237.1 cyclin A2 (CCNA2) -1.2 -5.7 -12.1 NC NC -2.1 -1.1 -8.6 -13.9
NM_004702.1 cyclin E2 (CCNE2) 1.6 -5.3 -3.2 NC -2.3 -1.7 -1.7 -4.9 -8.0
AF112857.1 cyclin E2 splice variant 1 mRNA 1.2 -3.5 -3.2 NC -2.0 -1.6 -1.4 -7.0 -8.6
NM_001761.1 cyclin F (CCNF) -1.5 -2.5 -3.7 -1.1 -1.1 -2.0 -1.4 -2.3 -2.8
AB012305.1 cyclin-dependent kinase 2 -1.7 -3.5 -5.3 -2.0 -2.1 -2.1 NC -2.8 -3.5
U30872.1 mitosin mRNA -1.2 -4.6 -6.1 NC -2.1 -1.3 NC -3.2 -7.0
NM_000389.1 cyclin-dependent kinase inhibitor 1A (p21, Cip1) 1.3 9.8 8.6 1.0 2.0 2.0 1.0 8.0 7.5
NM_006763.1 BTG family, member 2 (BTG2) 1.5 6.1 6.5 1.1 1.7 2.1 1.4 5.3 3.7
NM_006472.1 upregulated by 1,25-dihydroxyvitamin D-3 (VDUP1) 1.0 3.5 3.5 1.0 1.5 2.6 1.0 2.3 3.0
NM_001924.2 growth arrest and DNA-damage-inducible, alpha 1.4 7.5 7.5 NC 1.9 2.6 1.1 7.0 7.5
BC003637.1 Similar to DNA-damage-inducible transcript 3 1.0 2.6 2.6 1.1 2.1 2.5 NC 2.6 2.8
NM_014454.1 p53 regulated PA26 nuclear protein (PA26) 1.1 4.0 3.0 1.1 1.4 2.6 1.1 3.7 3.7
NM_004701.2 cyclin B2 (CCNB2) -1.1 -8 -13.9 NC 1.3 -1.3 -1 -4.9 -19.7
NM_001255.1 CDC20 (cell division cycle 20) -1.9 -90.5 -147 NC 1.6 -1.9 -1.6 -13 -157
NM_021873.1 cell division cycle 25B (CDC25B) -1.1 -1.6 -2.5 NC NC -1.4 -1 -2.3 -3.25
NM_001827.1 CDC28 protein kinase 2 (CKS2) -1.1 -4.6 -6.5 NC 1.6 -1.6 -1.2 -3.5 -5.7
NM_001168.1 survivin (BIRC5) -1.1 -27.9 -294 NC NC -1.6 NC -6.9 -181
Transcription, translation, oncogenesis, angiogenesis, other
NM_021953.1 forkhead box M1 (FOXM1) -1.2 -13.9 -42.2 -1.1 -1.2 -2.0 NC -2.8 -45.3
NM_000465.1 BRCA1 associated RING domain 1 (BARD1) -1.3 -1.9 -2.0 NC -1.1 -2.1 -1.2 -2.6 -4.9
NM_003368.1 ubiquitin specific protease 1 (USP1) NC -2.6 -1.6 NC -2.0 -1.4 NC -2.1 -1.9
NM_006716.1 activator of S phase kinase (ASK) -1.2 -6.5 -5.3 -1.2 -1.3 -2.0 -1.1 -4.6 -11.3
NM_003246.1 thrombospondin 1 (THBS1) NC -2.0 -3.5 -1.9 -1.4 -2.6 -1.1 -1.6 -4.6
NM_001147.1 angiopoietin 2 (ANGPT2) 3.5 3.5 8.0 1.7 5.3 8.0 -0.5 4.9 2.8
AF187858.1 angiopoietin-2 isoform-1 NC 2.6 4.3 NC 1.5 3.5 NC 2.0 2.0
NM_000435.1 Notch (Drosophila) homolog 3 (NOTCH3) 1.3 3.0 2.8 1.0 2.3 2.1 NC 2.1 3.0
NM_001674.1 activating transcription factor 3 (ATF3) NC 1.5 2.5 NC 1.7 2.5 NC 2.6 4.3
NM_003158.1 serinethreonine kinase 6 (STK6) -1.7 -11.3 -9.8 1.1 1.2 -1.7 -1.3 -8.6 -26
NM_003600.1 serinethreonine kinase 15 (STK15) -1.2 -3.7 -8.6 NC NC -1.6 -1.3 -4 -6.1
AF162704.1 androgen receptor mRNA NC 1.3 -1.6 1.2 1.3 -2.1 -1.1 -1.6 -2
Resistance to chemotherapeutic agents
NM_000693.1 aldehyde dehydrogenase 1A3 (ALDH1A3) NC 4.0 3.2 1.0 1.1 2.1 1.2 4.9 4.3
NM_005980.1 S100 calcium-binding protein P (S100P) 1.0 5.7 4.0 1.5 2.6 3.0 NC 2.6 2.6
The genes in this list showed a >2 fold change in expression in at least one time point in both mono and combination treatment.
NC: No change; Negative value: Decrease; Positive value: Increase.BMC Cancer 2005, 5:7 http://www.biomedcentral.com/1471-2407/5/7
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gene, BRCA1 associated RING domain, tumor-associated
nuclear protein p120, etc) in Taxotere and/or Furtulon
treated prostate cancer cells (Table 2 and 3). In contrast,
Taxotere and/or Furtulon up-regulated some genes that
are related to the induction of apoptosis (GADD45A,
GADD45B, etc), cell cycle arrest (p21CIP1, VDUP1, BTG,
etc), and tumor suppression (Table 2 and 3).
Combination treatment with Taxotere and Furtulon also
altered expression of some genes (CDC27, CDK9, p18,
IKKα, etc) that showed no change in mono-treatment
(Table 4 and 5), suggesting the synergic effects of combi-
nation treatment on some genes.
Taxotere and Furtulon also up-regulated some genes (S-
100P, ALDH1A3, casein kinase, annexin, etc) responsible
for chemotherapeutic resistance, suggesting the induction
of cancer cell resistance to these agents (Table 2 and 3).
Taxotere and Furtulon also showed differential effects on
PC3 cells with alteration of metastasis-related genes and
on LNCaP cells with down-regulation of survivin, cyclin B
& E, CDC2, CDC25, and specifically AR by Furtulon,
suggesting their effects mediated by both AR-independent
and dependent pathways (Table 2 and 3).
Target verification by real-time RT-PCR and western blot
To verify the alterations of gene expression at the mRNA
level, which appeared on the microarray, we chose repre-
sentative genes with varying expression profiles for real-
time RT-PCR and Western Blot analysis. The results of
real-time RT-PCR for these selected genes were in direct
agreement with the microarray data (Figure 2). The same
Table 4: Comparison of difference in gene expression between combination treatment and mono-treatment in PC3 cells
Gene Taxotere+Furtulon
6 h 36 h 72 h
Decrease in combination treatment, No change or increase in mono-treatment.
NM_001261.1 cyclin-dependent kinase 9 (CDC2-related kinase) (CDK9) -1.3 -1.2 -2.3
NM_016507.1 CDC2-related protein kinase 7 (CrkRS) NC -1.6 -2.3
AF080157.1 IkB kinase-a (IKK-alpha) NC -2.0 -1.6
U62296.1 transcription factor NF-YC -1.1 -1.7 -2.3
BC005003.1 nuclear transcription factor Y, gamma -1.1 -2.0 -2.1
BC001771.1 transcription factor IIF NC -1.6 -2.3
AI434345 activating transcription factor 1 NC -2.5 -2.6
BC001173.1 eukaryotic translation initiation factor 3 NC -1.3 -2.0
U78525.1 eukaryotic translation initiation factor (eIF3) NC -1.4 -2.0
NM_001814.1 cathepsin C (CTSC) NC -1.3 -2.0
NM_003377.1 vascular endothelial growth factor B (VEGFB) -2.1 NC NC
AF035620.1 BRCA1-associated protein 2 (BRAP2) -2.3 NC NC
AF035620.1 BRCA1-associated protein 2 (BRAP2) -2.3 -2.0 -1.4
NM_005346.2 heat shock 70 kD protein 1B (HSPA1B) -1.1 -2.1 -1.1
BC000478.1 heat shock 70 kD protein 9B NC -1.7 -2.3
NM_014278.1 heat shock protein (hsp110 family) (APG-1) -1.2 -1.3 -2.0
BC002526.1 Similar to heat shock protein, 110 kDa -1.1 -1.4 -2.1
Increase in combination treatment, No change or decrease in mono-treatment.
NM_000077.1 cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4) NC 1.7 2.1
NM_001262.1 cyclin-dependent kinase inhibitor 2C (p18, inhibits CDK4) NC 2.1 2.0
J03202.1 laminin B2 chain mRNA NC 1.3 2.0
BG164365 microtubule-associated protein 1B NC 2.3 2.0
NM_000594.1 tumor necrosis factor, member 2 NC 2.5 1.6
NM_001065.1 tumor necrosis factor, member 1A NC 2.0 1.9
BC000125.1 Similar to transforming growth factor, beta 1 -1.2 1.9 2.1
NM_005649.1 transcription factor 17 (TCF17) NC 1.1 2.3
NM_005923.2 mitogen-activated protein kinase kinase kinase 5 (MAP3K5) NC 1.6 2.1
NM_005204.1 mitogen-activated protein kinase kinase kinase 8 (MAP3K8) NC 2.3 4.3
NM_000785.1 cytochrome P450, subfamily XXVIIB NC 2.1 1.5
NM_002960.1 S100 calcium-binding protein A3 (S100A3) NC 2.5 2.5
NM_002962.1 S100 calcium-binding protein A5 NC 8.6 10.6
NC: No change; Negative value: Decrease; Positive value: Increase.
The genes in this list showed a >2 fold change in expression in at least one time point in combination treatment.BMC Cancer 2005, 5:7 http://www.biomedcentral.com/1471-2407/5/7
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alternations of gene expression were observed by real-
time RT-PCR analysis, although the fold change in the
expression level was not exactly same between these two
different analytical methods. The results of Western Blot
analysis were also in direct agreement with the microarray
and real-time RT-PCR data (Figure 3 and our earlier report
[11]). These results support the findings obtained from
microarray experiments.
Discussion
It has been known that Taxotere binds to microtubules
while Capecitabine is incorporated into DNA, inhibiting
the bioprocess in cancer cells [4,13]. However, the precise
molecular mechanisms for inhibiting cancer cell growth
by Taxotere and/or Capecitabine have not been fully elu-
cidated. From gene expression profiles of Taxotere and/or
Capecitabine treated prostate cancer cells, we found that
these chemotherapeutic agents caused alterations in the
expression of many genes related to the control of cell pro-
liferation, apoptosis, transcription, translation, cell
signaling, oncogenesis, and angiogenesis (Figure 4),
although the cellular target of Taxotere or Capecitabine
appears to be different.
It has been well known that CDCs regulate the molecules
related to the cell cycle initiation and progression and that
cyclins associate with cyclin-dependent protein kinases
(CDKs) and CDCs to control the process of cell cycle
[23,24]. The CDK inhibitors including p21WAF1, p16INK4A,
and p18INK4C have been demonstrated to arrest the cell
cycle and inhibit the growth of cancer cells [23,24]. Our
results showed that Cyclins (cyclin A2, cyclin E2, cyclin F,
cyclin B1), CDK2, CDC2, and other cell growth promo-
tion genes (pescadillo, spermidine synthase, mitotin) [25-
27] were down-regulated in Taxotere and/or Furtulon
treated prostate cancer cells, while CDK inhibitor p21WAF1
and other growth inhibitor genes (BTG2, VDUP1, anti-
proliferative B-cell translocation gene 1) [28,29] were up-
regulated, suggesting that Taxotere and/or Furtulon inhib-
ited the growth of prostate cancer cells through the arrest
of cell cycle and the inhibition of cell proliferation (Figure
4). The down-regulation of CDC27, CDK9, EGF, and
FGF12B, and up-regulation of p16INK4A and p18INK4C were
also observed in combination treatment but not in mono-
treatment, suggesting the synergic effect of combination
treatment. These observations are novel in Taxotere and/
or Furtulon treated prostate cancer cells.
Induction of apoptosis by chemotherapeutic agents also
leads to the inhibition of cancer cell growth. It has been
reported that Taxotere is able to induce apoptosis by cas-
pase-3 dependent or independent cell death mechanism
[30]. Capecitabine may induce apoptosis through Fas/
FasL or Bax/Bcl-2 pathway [31,32]. From gene expression
Table 5: Comparison of difference in gene expression between combination treatment and mono-treatment in LNCaP cells
Gene Taxotere+Furtulon
6 h 36 h 72 h
Decrease in combination treatment, No change or increase in mono-treatment.
NM_001256.1 cell division cycle 27 (CDC27) NC -1.6 -2.0
NM_001963.2 epidermal growth factor (beta-urogastrone) (EGF) NC -3.5 -1.9
NM_004113.2 fibroblast growth factor 12B (FGF12B) NC -4.3 -1.2
U13022 negative regulator of programmed cell death ICH-1S (Ich-1) NC -2.3 -2.0
AF249273.1 Bcl-2-associated transcription factor short form mRNA NC -1.7 -2.3
NM_001071.1 thymidylate synthetase (TYMS) NC -1.4 -2.6
AF005068.1 breast and ovarian cancer susceptibility protein (BRCA1) NC -4.6 -17.1
NM_012068.2 activating transcription factor 5 (ATF5) NC -2.0 -2.8
NM_021809.1 TGF(beta)-induced transcription factor 2 (TGIF2) NC -1.6 -2.1
NM_001412.1 eukaryotic translation initiation factor 1A (EIF1A) NC -1.2 -2.3
NM_002758.1 mitogen-activated protein kinase kinase 6 (MAP2K6) NC -1.7 -2.1
Increase in combination treatment, No change or decrease in mono-treatment.
NM_006034.1 p53-induced protein (PIG11) NC 6.1 7.5
NM_000227.1 laminin, alpha 3 NC 1.7 2.0
NM_000094.1 collagen, type VII, alpha 1 (COL7A1) NC 1.4 6.5
NM_016437.1 tubulin, gamma 2 (TUBG2) NC 1.4 2.1
NM_000853.1 glutathione S-transferase theta 1 (GSTT1) NC 2.0 2.1
NC: No change; Negative value: Decrease; Positive value: Increase.
The genes in this list showed a >2 fold change in expression in at least one time point in combination treatment.BMC Cancer 2005, 5:7 http://www.biomedcentral.com/1471-2407/5/7
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profile, we found that Taxotere and/or Furtulon increased
level of growth arrest and DNA-damage-inducible alpha
(GADD45A), GADD45B, p53 regulated PA26 nuclear
protein (PA26), and p53-induced protein 11 (PIG11), all
of which are related to the induction of apoptotic proc-
esses. GADD45A and GADD45B have been known to pro-
mote apoptosis and regulate G2/M arrest [33]. PA26 is a
target of the p53 tumor suppressor and a member of the
GADD family with the properties of inducing apoptosis
[34]. PIG11 as a downstream target of p53 is also involved
in the apoptotic processes [35]. The combination treat-
ment also showed down-regulation of negative regulator
of programmed cell death ICH-1S and Bcl-2-associated
transcription factor, which was not occurred in mono-
treatment. The induction of apoptosis mediated by
GADD45A, GADD45B, PA25, and PIG11 could be
another molecular mechanism by which Taxotere and/or
Furtulon inhibit the growth of prostate cancer cells.
Real-time RT-PCR showing the altered expression of specific genes in Taxotere and Furtulon treated PC3 and LNCaP cells Figure 2
Real-time RT-PCR showing the altered expression of specific genes in Taxotere and Furtulon treated PC3 and LNCaP cells. (C: 
control; T+F: Taxotere and Furtulon combination treatment.)BMC Cancer 2005, 5:7 http://www.biomedcentral.com/1471-2407/5/7
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We also found that Taxotere and/or Furtulon inhibited
the expression of transcription factors (FOXM1, ATF5,
TFAM, TAFII31L), translation factors (EIF1A, EIF5A),
oncogene (GRO1, GRO3, BRCA1-associated protein,
tumor-associated nuclear protein p120), and heat shock
protein, and up-regulated the genes for differentiation
(prostate differentiation factor). These results are novel,
and suggest the beneficial effects of Taxotere and/or
Furtulon on the inhibition of cancer cell growth and
oncogenesis.
It is important to note that Taxotere and/or Furtulon also
up-regulated the expression of some genes which are
known to induce cell resistance to chemotherapeutic
agents and to favor cell survival. Among these genes, cal-
cium-binding protein S100P has been found to be highly
expressed in cells which develop acquired resistance to
anti-tumor agents [36]. The overexpression of aldehyde
dehydrogenase 1 (ALDH1) has also been detected solely
in classical multidrug resistance cancer cells [37,38]. It has
been reported that Annexin-I, casein kinase 1, and cispla-
tin-resistance associated protein expressions modulate
drug resistance in tumor cells [39,40]. The up-regulation
of these molecules by Taxotere and/or Furtulon could
induce cell resistance to chemotherapeutic agents. Also,
Taxotere and/or Furtulon were found to up-regulate the
expression of Notch 3, angiopoietin, activating transcrip-
tion factor 3, which could favor cell survival [41-43]. Fur-
ther in depth mechanistic studies are needed to address
these issues. The investigation on overcoming these
unbeneficial effects with other agents must be devised,
which is ongoing in our laboratory.
Taxotere showed no effect on AR expression while Furtu-
lon down-regulated AR expression in LNCaP cells, sug-
gesting that the combination could be superior in AR-
positive cells. The genes altered by Taxotere and/or Furtu-
lon with respect to the control of cell growth, apoptosis,
transcription, oncogenesis, and metastasis in androgen
insensitive PC3 cells are different from that in androgen
sensitive LNCaP cells, suggesting that the effects of
Taxotere and Furtulon may be mediated by both AR-
dependent and independent signaling pathways. We
observed up-regulation of tissue inhibitor of metallopro-
teinase 1 (TIMP1), TIMP2, and protease inhibitor 3 in
Taxotere and/or Furtulon treated PC3 cells, suggesting
that Taxotere and/or Furtulon may exert anti-metastatic
effect. However, we also observed increase in the expres-
sion of MMP1, MMP9, cathepsin B, uPA, and tPA in Tax-
otere and Furtulon treated PC3 cells, therefore, more
experimental studies are needed to reveal the overall effect
of Taxotere and Furtulon on metastatic processes. These
results were not observed in androgen sensitive LNCaP
cells, suggesting difference in effects that could be medi-
ated through different cell signal transduction pathways.
Conclusions
In conclusion, Taxotere and/or Furtulon directly and indi-
rectly caused changes in the expression of many genes that
are critically involved in the control of cell proliferation,
apoptosis, transcription, translation, oncogenesis,
angiogenesis, metastasis, and drug resistance (Figure 4).
These findings could provide molecular information for
further investigation on the mechanisms by which Taxo-
tere and Furtulon exerts their pleiotropic effects on pros-
tate cancer cells. These results could also be important in
devising mechanism-based targeted therapeutic strategies
for prostate cancer, especially in devising combination
therapy for drug resistant prostate cancers. However, fur-
ther in-depth investigations are needed in order to estab-
lish cause and effect relationships between these altered
genes and therapeutic response in prostate cancer cells.
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Western Blot analysis showing the altered expression of spe- cific genes in Taxotere and Furtulon treated PC-3 or LNCaP  cells Figure 3
Western Blot analysis showing the altered expression of spe-
cific genes in Taxotere and Furtulon treated PC-3 or LNCaP 
cells. (C: control; T: Taxotere treatment; F: Furtulon treat-
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Effects of Taxotere and Furtulon on cell cycle, apoptosis, and other pathway related gene expression analyzed and visualized by  GenMAPP software integrated with cDNA microarray data Figure 4
Effects of Taxotere and Furtulon on cell cycle, apoptosis, and other pathway related gene expression analyzed and visualized by 
GenMAPP software integrated with cDNA microarray data. A: PC3 cells. B: LNCaP cells. (positive value: increase in fold 
change; negative value: decrease in fold change; A: PC3 cells; B: LNCaP cells)BMC Cancer 2005, 5:7 http://www.biomedcentral.com/1471-2407/5/7
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